In some instances, the dry stage of macular degeneration can turn into the wet stage. If ACTC treats or prevent Dry AMD there will be less cases of wet AMD. This is how I understand.
I have reread that article I posted and cannot see where it mentions "wet" macular degeneration. I do not have foreknowledge of these drugs or in particular Avastin's cancer drug being used for "wet" macular degeneration and if that is the case my apoligies.
At any rate I like the idea that ACTC will have an opportunity render these drugs obsolete and in a 25-30 billion dollar market.
Market Data 
Markets 
AI
